Request Free Sample
×
Cancer Biological Therapy Market
ID: MRFR/Pharma/0173-CR
85 Pages
April 2017
EMEA Cancer Biological Therapy Market information, by type (monoclonal antibodies, interferons, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines and others) by end users (hospitals & clinics, cancer research centers, laboratories) - Forecast to 2035
Industry Developments
In January 2020, a biopharmaceutical company called ArQule Inc joined hands with Merck and Co. to study the growth and development of a device for kinase inhibitor to treat cancer patients. AVEO Oncology was successful in getting FDA approval and clearance in June 2020, for the discovery and development of a new drug tivozanib for refractory renal cell disruption and carcinoma. Glaxo Smith Kline PLC joined hands with TESARO Inc. in the January of 2019 to pipeline and expand the study of oncology and see if it fits to provide commercial revenue to the EMEA Cancer biological therapy market.
Market Segmentation
EMEA Cancer biological therapy market Competitive Insights
- Bayer AG
- Novartis AG
- Johnson and Johnson
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Amgen Inc .
- AstraZeneca plc.
- Celgene Corporation
- Engeneic Ltd.
- Eli Lily and Company
- Merck and Co.
- Hoffmann-La Roche Ag.
- Teva Pharmaceutical
Few of the key market players in the EMEA Cancer biological therapy market are
- Bayer AG
- Novartis AG
- Johnson and Johnson
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Amgen Inc .
- AstraZeneca plc.
- Celgene Corporation
- Engeneic Ltd.
- Eli Lily and Company
- Merck and Co.
- Hoffmann-La Roche Ag.
- Teva Pharmaceutical
Report Scope
| Attribute/Metric | Details |
| Market Size 2032 | USD 14.50 Billion |
| CAGR | 9.22% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By type, end users |
| Geographies Covered | Europe, Middle East, and Africa |
| Key Vendors | Bayer AG, Novartis AG, Johnson and Johnson, Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc., AstraZeneca plc., Celgene Corporation, Engeneic Ltd., Eli Lily and Company, Merck and Co., Hoffmann-La Roche Ag., Teva Pharmaceutical |
| Key Market Opportunities | Rising cancer incidences among the geriatric populations on a global level |
| Key Market Drivers | Ongoing research and development in cancer immunotherapy, such as CAR-T cell therapies |
Market Highlights
Author
Leave a Comment
FAQs
At what CAGR is theEurope, the Middle East, and Africa Cancer Biological Therapy Market projected to grow during the forecast period?
Europe, the Middle East, and Africa Cancer Biological Therapy Market is projected to grow at 9.22% CAGR during the forecast period.
What are the different end use industries of EMEA Cancer Biological Therapy Market?
Different end use industries of EMEA cancer biological therapy include laboratories, cancer research centers, and hospitals & clinics.
Which region will dominate the EMEA Cancer Biological Therapy Market?
Europe is predicted to dominate the EMEA Cancer Biological Therapy Market.
Which type segment will dominate the EMEA Cancer Biological Therapy Market?
Monoclonal antibodies will dominate the EMEA Cancer Biological Therapy Market.
Download Free Sample
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director